A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) subjects (PREDICTRA)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms PREDICTRA
- Sponsors AbbVie
- 02 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 15 Dec 2016 Planned End Date changed from 1 Feb 2018 to 1 Jan 2020.